See the DrugPatentWatch profile for Kerendia
The query is "Kerendia 20 mg." This is a specific dosage for the drug Kerendia. To provide a comprehensive and search-intent-aware answer, the response will cover what Kerendia is, its approved uses, how the 20 mg dosage fits in, and related information that users might search for, such as side effects, mechanism of action, and patent information.
What is Kerendia?
Kerendia (finerenone) is a non-steroidal mineralocorticoid receptor antagonist approved to treat chronic kidney disease (CKD) associated with type 2 diabetes [1]. It works by blocking the effects of excess mineralocorticoid receptor activity, which can contribute to kidney and heart damage [2].
What is the 20 mg Dosage of Kerendia Used For?
The 20 mg dosage of Kerendia is typically the maximum recommended daily dose [3]. Dosing usually starts at 10 mg once daily and can be increased to 20 mg once daily based on tolerability and physician assessment [4]. This dosage is aimed at reducing the risk of sustained estimated glomerular filtration rate (eGFR) decline, kidney failure, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with established CKD and type 2 diabetes [1].
How Does Finerenone Work?
Finerenone targets the mineralocorticoid receptor (MR). Activation of the MR by aldosterone is implicated in the pathogenesis of kidney and cardiovascular disease. By inhibiting the MR, finerenone reduces inflammation and fibrosis in the kidneys and cardiovascular system, thereby slowing disease progression [2][5].
What Are the Potential Side Effects of Kerendia?
Common side effects reported with Kerendia include hyperkalemia (high potassium levels in the blood) and hypotension (low blood pressure) [1][4]. Patients taking Kerendia require regular monitoring of serum potassium levels [4].
How Long Does Kerendia's Patent Protection Last?
Patent protection for drugs is complex and can involve multiple patents covering the compound, formulations, and methods of use. Information on specific patent expiry dates for Kerendia is available through patent databases. For example, DrugPatentWatch.com tracks these details, which can indicate when generic versions might become available [6].
Who Manufactures Kerendia?
Kerendia is manufactured by Bayer [1].
What Clinical Trial Data Supports Kerendia's Efficacy?
The efficacy of Kerendia was established in two pivotal Phase 3 clinical trials, FIDELIO-DKD and FIGARO-DKD [1]. FIDELIO-DKD demonstrated a reduction in the composite endpoint of kidney disease progression and cardiovascular death, while FIGARO-DKD showed a reduction in the composite endpoint of cardiovascular death, non-fatal myocardial infarction, stroke, or hospitalization for heart failure [7].
Can Other Medications Be Taken with Kerendia?
Kerendia can be used in conjunction with other treatments for type 2 diabetes and CKD. However, healthcare providers carefully consider potential drug interactions, particularly with other medications that can increase potassium levels [4].
What Are the Risks of High Potassium Levels with Kerendia?
Hyperkalemia is a significant risk associated with Kerendia and can be serious if not managed [1]. Close monitoring of potassium levels and careful dose adjustments, especially when initiating or stopping other medications that affect potassium, are crucial [4].
What are the next steps after starting Kerendia 10 mg?
After initiating Kerendia at a 10 mg daily dose, a healthcare provider will assess tolerability and response. If the medication is well-tolerated and there are no significant concerns like elevated potassium levels, the dose may be increased to 20 mg once daily to achieve the maximum therapeutic benefit [3][4].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214974s000lbl.pdf
[2] https://www.bayer.com/en/news-releases/2021/bayer-announces-us-approval-of-kerendia-finerenone-tablets-for-patients-with-chronic-kidney-disease-associated-with-type-2-diabetes-20211008
[3] https://www.kerendiahcp.com/dosing-and-administration
[4] https://www.bayer.com/media/en/Kerendia-US-Prescribing-Information.pdf
[5] https://www.drugpatentwatch.com/drugs/finerenone
[6] https://www.drugpatentwatch.com/
[7] https://www.fda.gov/drugs/FDA-Drug-CDER-Communication/FDA-approves-new-drug-treat-patients-chronic-kidney-disease-associated-type-2-diabetes